TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29669963
Drug: Intravenous Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Nicorandil
Study: 27549626
Drug: Vaccine-primed group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-primed group (VP)
Study: 18371483
Drug: Estimated GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated GFR <60 mL/min
Study: 16618300
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) immediately after inhalational induction
Study: 16618300
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of tropisetron (0.1 mg x kg(‐1), max 2 mg) after the end of surgery before extubation
Study: 16618300
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of tropisetron
Study: 16618300
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of tropisetron
Study: 16618300
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and late administration of tropisetron
Study: 11007220
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.i.d. for 30 days
Study: 8831847
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotic suspension only)
Study: 8173689
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of felodipine plus metoprolol 5/50‐10/100 mg (FM)
Study: 8173689
Drug: Felodipine 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5‐10 mg (F)
Study: 8173689
Drug: Metoprolol 50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50‐100 mg (M)
Study: 3527886
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LH); n = 29
Study: 3527886
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH); n = 27
Study: 27189681
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (25 mg/kg, intravenous, single dose)
Study: 27189681
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (single dose)
Study: 24059690
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily (titrated to 100 mg for non-responders)
Study: 23420326
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (group M) treated with pioglitazone
Study: 23420326
Drug: Gallstone group
Normalized name: Bos taurus gallstone preparation
DrugBank: Bos taurus gallstone (DB14248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallstone group (group G)
Study: 16324915
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + 4 mg rosiglitazone
Study: 16324915
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + 8 mg rosiglitazone
Study: 14653829
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) 2 x 320 mg plant extract t.d.s.
Study: 8971428
Drug: Theophylline (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (loading dose 5 mg kg‐1 over 20 min, followed by 0.5 mg kg‐1 min‐1)
Study: 8971428
Drug: Dipyridamole (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.21 mg kg‐1 h‐1)
Study: 1317691
Drug: Thiorphan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (2.5 mg/ml, 0.5 ml)
Study: 6742538
Drug: Flunitrazepam (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.33 mg X kg‐1)
Study: 6742538
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg X kg‐1)
Study: 6742538
Drug: Midazolam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.4 mg X kg‐1)
Study: 29670416
Drug: Intravenous Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Oxycodone
Study: 30875090
Drug: Intravenous Sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Sufentanil
Study: 24780450
Drug: Tight glycaemic
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycaemic control (TGC): insulin by intravenous infusion titrated to maintain blood glucose between 4.0 and 7.0 mmol/l.
Study: 24780450
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management (CM): insulin by intravenous infusion only if blood glucose exceeded 12.0 mmol/l on two samples at least 30 minutes apart; insulin was stopped when blood glucose fell below 10.0 mmol/l.
Study: 22855332
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg twice a day)
Study: 20532723
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 3 mg/kg/hr infusion)
Study: 20388468
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine interventions
Study: 12492906
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CHX 2 x daily for 30 s (0.1% CHX)
Study: 12492906
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg CHX 2 x daily for 60 s (0.06% CHX)
Study: 12492906
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml SFAF rinse 1 x daily for 30 s
Study: 12492906
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg CHX 2 x daily for 30 s (0.06% CHX)
Study: 12492906
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml placebo 2 x daily for 60 s
Study: 8525690
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 0, 2, and 6 months of age
Study: 8525690
Drug: DTP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP and oral polio vaccines
Study: 8525690
Drug: Polio vaccine
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polio vaccine
Study: 8525690
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine with DTP and polio vaccines
Study: 2359570
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg three times daily during menses)
Study: 2359570
Drug: Norethisterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone (5 mg twice daily on days 19-26 of the cycle)
Study: 27486204
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 250 mg daily for 8 weeks
Study: 21525260
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea polyphenols beverage providing 1402 mg total catechins/d
Study: 21525260
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea polyphenols (0.5, 1.0, and 2.0 g) in a separate study
Study: 16537867
Drug: Heliox inhalation
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox inhalation for 1 hour
Study: 16537867
Drug: Airox inhalation
Normalized name: Agkistrodon piscivorus antivenin / Crotalus adamanteus antivenin / Crotalus atrox antivenin / Crotalus scutulatus antivenin Injection [CroFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airox inhalation for 1 hour
Study: 10831074
Drug: i.v. mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. mycophenolate mofetil (MMF) 1 g Q12h
Study: 10831074
Drug: i.v. mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. mycophenolate mofetil (MMF) 1 g b.i.d.
Study: 9085956
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (3 mg/kg)
Study: 9085956
Drug: 0.25% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% lidocaine (1.5 mg/kg) with 1 microg/kg of fentanyl and 0.5 mg of pancuronium
Study: 8025983
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg daily)
Study: 3028660
Drug: Ifosfamide administered
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide administered with mesna (IFO/M)
Study: 25055491
Drug: Propofol (0.3‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.3‐2 mg/kg per hour)
Study: 22079736
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy combined with long-term androgen deprivation therapy
Study: 20535924
Drug: Periodontal initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Periodontal initial therapy together with Chinese herbal compound (TCM) for clearing heat and detoxification
Study: 20535924
Drug: Periodontal initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Periodontal initial therapy alone (Control group)
Study: 17214996
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg (C600)
Study: 17214996
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg (C300)
Study: 11819153
Drug: Idebenone 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 360 mg/day
Study: 11819153
Drug: Tacrine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine up to 160 mg/day
Study: 10566611
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy combinations
Study: 10566611
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with newer agents (vinorelbine or paclitaxel)
Study: 8948920
Drug: Dinoprostone 0.5
Normalized name: dinoprostone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 0.5 mg in gel form (intracervically applied)
Study: 9659017
Drug: midazolam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.08 mg.kg‐1
Study: 2021987
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg.kg‐1 with perphenazine 2.5‐5.0 mg im
Study: 7021431
Drug: Propiram 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiram 50 mg
Study: 7021431
Drug: Propiram 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiram 100 mg
Study: 31901794
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Study: 31347920
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga therapy (6 standardized 35-min weekly sessions)
Study: 31347920
Drug: Conventional therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapeutic exercises (CTEs) (6 standardized 35-min weekly sessions)
Study: 22537508
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga therapy
Study: 23192725
Drug: Midazolam continuous
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam continuous infusion in hypothermic patients
Study: 23192725
Drug: Midazolam as
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam as sedative in control group
Study: 23192725
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pharmacokinetics between groups
Study: 22042783
Drug: FAC +
Normalized name: 4'-Thio-fac
DrugBank: 4'-Thio-fac (DB16071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC + G-CSF (5-FU 600 mg/m², doxorubicin 60 mg/m², cyclophosphamide 1000 mg/m² every 18 days for four cycles)
Study: 22042783
Drug: FAC (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (5-FU 500 mg/m², doxorubicin 50 mg/m², cyclophosphamide 500 mg/m² every 21 days for four cycles)
Study: 22042783
Drug: FAC +
Normalized name: 4'-Thio-fac
DrugBank: 4'-Thio-fac (DB16071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC + G-CSF
Study: 10731301
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulphur pool and bathing in the Dead Sea
Study: 8550130
Drug: Nitroxazepine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroxazepine (25 mg PO, HS)
Study: 1960313
Drug: Intravenous ribose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ribose (3.3 mg/kg per min)
Study: 6173512
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment (traditional, stimulus-response type treatment of specific language deficits)
Study: 6173512
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (designed to improve communication through group interaction and discussion, no direct treatment of specific language deficits)
Study: 15678736
Drug: Propofol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (30 mg kg(‐1)h(‐1)) + Fentanyl (2 microg kg(‐1))
Study: 15678736
Drug: Propofol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (30 mg kg(‐1)h(‐1)) + Normal Saline
Study: 9845405
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg (effervescent)
Study: 9845405
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg (tablet)
Study: 9845405
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg (effervescent)
Study: 9845405
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg (tablet)
Study: 9845405
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg (tablet) vs Cimetidine 200 mg (tablet)
Study: 2569435
Drug: Sulphasalazine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine at 1.5 g and 3.0 g
Study: 28243685
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 mg dimemorfan phosphate tablets
Study: 28243685
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 mg dimemorfan phosphate tablets under fed conditions
Study: 28243685
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg dimemorfan phosphate tablets
Study: 28243685
Drug: Multiple-dosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dosing of 20 mg dimemorfan phosphate tablets 3 times per day
Study: 28243685
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 mg dimemorfan phosphate tablets under fasting conditions
Study: 25512675
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 2 weeks at weeks 0-4; CZP 200 mg every 2 weeks at weeks 6-16
Study: 25512675
Drug: Placebo→CZP (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo→CZP (placebo at weeks 0-2; CZP loading dose at weeks 2-6; CZP 200 mg every 2 weeks at weeks 8-16)
Study: 24259595
Drug: Medication Monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication Monitoring and Optimization (MeMO) program
Study: 18053580
Drug: Light room
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light room therapy
Study: 2576667
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg/day (Control)
Study: 2576667
Drug: Indenolol, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol, 60 mg/day
Study: 1269217
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg dextroamphetamine
Study: 1269217
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dextroamphetamine
Study: 1269217
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dextroamphetamine
Study: 15968233
Drug: Once-daily atomoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily atomoxetine
Study: 9849290
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for laryngospasm
Study: 2511023
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (Group A, n = 11)
Study: 1233383
Drug: Chlorpromazine-imipramine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine-imipramine combination
Study: 30703444
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 mg moguisteine
Study: 30703444
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg moguisteine
Study: 30703444
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg moguisteine
Study: 30703444
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 200 mg moguisteine (three times daily for five consecutive days)
Study: 19373517
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care participants received cessation pamphlets and information on local treatment programs
Study: 15546073
Drug: Micafungin 50
Normalized name: micafungin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 50 mg (1 mg/kg for patients weighing <50 kg)
Study: 15546073
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg (8 mg/kg for patients weighing <50 kg)
Study: 11444499
Drug: Nicorandil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (0.1 mg/kg) administered during cardiopulmonary bypass
Study: 7997395
Drug: Digoxin tablets
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin tablets
Study: 7997395
Drug: Digoxin capsules
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin capsules
Study: 7997395
Drug: Control (tablets)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (tablets)
Study: 7997395
Drug: Control (capsules)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (capsules)
Study: 26764884
Drug: Sofosbuvir therapy
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir therapy with peginterferon and ribavirin
Study: 23252003
Drug: HTESB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTESB therapy
Study: 17183628
Drug: Potent antiretroviral
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent antiretroviral therapy (ART)
Study: 14504915
Drug: 7.5 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/week of methotrexate
Study: 14504915
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of sulphasalazine
Study: 30453379
Drug: 22 G
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 G needle
Study: 26407017
Drug: 25 G
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G needle
Study: 3986068
Drug: Extradural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural analgesia (local anaesthetics from before skin incision until 24 h after skin incision plus extradural morphine 4 mg every 12 h from 3 h to 72 h after skin incision)
Study: 3986068
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with low‐dose fentanyl plus intermittent systemic morphine for postoperative pain
Study: 31295161
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg q.d. for 4 weeks
Study: 30328976
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump A at 100 mL/h
Study: 30328976
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump A at 300 mL/h
Study: 30328976
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump B at 100 mL/h
Study: 30328976
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump B at 300 mL/h